Thomas J. Schall has bought stock on 3 days since Jun 2025

Thomas J. Schall, Ph.D. (age 65) is the Chairman of the Board of Directors at Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company, having joined the board in March 2024 and been appointed Chairman on September 16, 2025.( He is an independent Class I director serving through the 2028 annual meeting, and a member of the Compensation Committee.( On January 15, 2026, Schall purchased 21,645 shares of IMRX Class A common stock at an average price of $4.6681 per share, increasing his direct holdings to 74,530 shares.(

Schall founded ChemoCentryx, Inc. in 1997 and served as its President, CEO, and Chairman for 25 years until its $4 billion acquisition by Amgen in 2022, during which he led the FDA approval of Tavneos® for ANCA-associated vasculitis.( His earlier career includes scientist roles at DNAX Research Institute (Schering-Plough) from 1993–1997 and Genentech prior to 1993, contributing to chemokine receptor discoveries.( He holds a B.S. in Biology from Northern Illinois University and a Ph.D. in Cancer Biology from Stanford University.(

Written by Perplexity from public sources.